Skip to main content
. 2024 Dec 11;8(3):e202403122. doi: 10.26508/lsa.202403122

Figure 8. Pharmacologic SGK3 inhibition elevates γ-secretase-derived N1ICD and Notch signaling.

Figure 8.

(A) Western blot analysis reveals that serum-starved, VPS34-IN1-treated, MCF10A cells fail to phosphorylate the SGK3 target NDRG1 upon EGF treatment. (B) Western blot analysis reveals that pharmacologic VPS34-IN1 treatment enhances N1ICD levels. (C) RT-qPCR analysis shows that pharmacologic VPS34-IN1 treatment significantly enhances the expression of the Notch target gene HEY1. (D) Western blot analysis confirms that a specific pharmacological treatment with PROTAC1 enhances N1ICD levels. ** indicates P < 0.01.